Nippon Life Global Investors Americas Inc. Purchases Shares of 4,300 IQVIA Holdings Inc. $IQV

Key Points

• Nippon Life Global Investors Americas acquired 4,300 IQVIA shares worth approximately $831,000, while institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting $3.15 in adjusted EPS versus a $3.03 estimate and $4.37 billion in revenue, up 8.7% year over year. The company also authorized a $2 billion share buyback, covering up to 6.8% of outstanding shares.
• Analysts maintain a positive outlook, with IQVIA carrying a “Moderate Buy” consensus rating and an average price target of $241.88; however, insiders have sold 12,913 shares worth about $3.1 million over the past 90 days.

Nippon Life Global Investors Americas Inc. acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,300 shares of the medical research company's stock, valued at approximately $831,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. International Assets Investment Management LLC bought a new position in IQVIA in the fourth quarter worth approximately $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA during the 4th quarter worth $27,000. CrossGen Wealth LLC bought a new stake in shares of IQVIA during the 4th quarter valued at $28,000. Activest Wealth Management increased its stake in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company's stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Finally, Financial Freedom LLC purchased a new stake in shares of IQVIA in the 1st quarter worth $25,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Transactions at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company's stock, valued at $317,143.96. This represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is owned by company insiders.

IQVIA Trading Down 0.2%

IQV stock opened at $236.18 on Monday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $251.36. The business has a 50 day simple moving average of $206.65 and a two-hundred day simple moving average of $186.72. The company has a market capitalization of $38.87 billion, a price-to-earnings ratio of 29.30, a PEG ratio of 2.01 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company's quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Stifel Nicolaus raised their price objective on IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. TD Cowen lifted their price objective on IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. HSBC reissued a "buy" rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Finally, BMO Capital Markets upped their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source